A Phase 1 Study of C-TIL051 and NKTR-255 in Non-Small Cell Lung Cancer

Study Description

A Study to Test a New Combination Immunotherapy Treatment for Advanced Non-Small Cell Lung Cancer

Study Details

Registry ID:

NCT05676749

Conditions:

Metastatic Non Small Cell Lung Cancer

Phase:

Phase 1

Target Enrollment:

1 participants

Start Date:

February 29, 2024

Age Range:

18–999 years

Healthy Volunteers:

No

Study Locations (4 sites)

• Duke Center for Cancer Immunotherapy
  Raleigh, North CarolinaUnited States, United States
• Duke Cancer Institute
  Raleigh, North CarolinaUnited States, United States
• Allegheny Health Network-West Penn Hospital
  Pittsburgh, PennsylvaniaUnited States, United States
• Ochsner MD Anderson Cancer Center
  New Orleans, LouisianaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →